Brentuximab vedotin is an antibody-drug conjugate directed to CD30, a defining marker of classical HL and expressed on the surface of several types of peripheral T-cell lymphomas. The intention-to-treat analysis examined PFS outcomes per investigator assessment in the population of 1,334 patients <60 years old at 3 years, by cycle 2 positron-emission tomography (PET2). The ECHELON-1 trial achieved its primary endpoint with the combination of brentuximab vedotin plus AVD resulting in a statistically significant improvement in modified PFS vs the control arm of ABVD, as assessed by independent review facility (HR 0.77; P=0.035). Modified PFS was defined as time to progression, death, or evidence of non-complete response after completion of frontline therapy per independent review facility followed by subsequent anticancer therapy. Key findings from this updated analysis include:
- The 3-year PFS for all patients in the brentuximab vedotin + AVD arm was 83.1% compared with 76% in the ABVD arm (HR 0.70), a difference of 7.1%.
- PFS benefit at 3 years for brentuximab vedotin + AVD was observed for all patients independent of PET2 status, including in patients <60 years old.
- PET2-scan was negative in 85.8% in the brentuximab vedotin + AVD arm compared with 79.5% in the ABVD arm (HR 0.69), a difference of 6.3%.
- PET2-scan result was positive in 67.7% in the brentuximab vedotin + AVD arm compared with 51.5% in the ABVD arm (HR 0.59), a difference of 16.2%.
- Consistently higher PFS was observed among patients treated with brentuximab vedotin + AVD compared with ABVD across most pre-specified subgroups, including disease stage, age, and prognostic score.
- In the brentuximab vedotin + AVD arm, peripheral neuropathy events were observed in 67% of patients compared with 43% in the ABVD arm. The 3-year analysis shows that among patients with peripheral neuropathy, 78% of in the brentuximab vedotin + AVD arm and 83% in the ABVD arm reported complete resolution or improvement at last follow-up.
- Horwitz S, et al. Abstract S820, 24th Congress of the EHA, 13-16 June 2019, Amsterdam, the Netherlands.
Posted on
Previous Article
« Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM Next Article
Initial data on AMV564 in patients with relapsed/refractory AML »
« Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM Next Article
Initial data on AMV564 in patients with relapsed/refractory AML »
Table of Contents: EHA 2019
Featured articles
Editor Biography
Interview with EHA President Prof. Pieter Sonneveld
Myeloid Malignancies
Residual disease in AML patients prior to stem cell transplant increases relapse risk
Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML
Initial data on AMV564 in patients with relapsed/refractory AML
Overcoming the ādonāt eat meā signal in AML and MDS
Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia
Guadecitabine vs treatment of choice in AML
Lymphoid Malignancies
Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL
CAR-T cell therapy in ALL as breakthrough advance
Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma
Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma
Obinutuzumab/polatuzumab in follicular lymphoma
Exciting survival data for ibrutinib vs placebo in treatment-naĆÆve, early-stage CLL
ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL
Venetoclax-obinutuzumab combination elicits high response rates in CLL
Myeloma
CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma
Chimeric antigen receptor T cell therapy in multiple myeloma
Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM
Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM
Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis
Venetoclax for multiple myeloma: effective but some safety concerns
Benign Haematology
New sickle cell drug voxelotor boosts levels of haemoglobin
Positive initial data evaluating the safety and efficacy of IMR-687 for treatment of sickle cell disease
Haematopoietic stem cell transplantation improves stroke risk in children with sickle cell anaemia
Early trial data shows positive results for treating anaemia in patients with end-stage renal failure
Bench-to-Bedside
Transformation of foetal haematopoietic stem and progenitor cells in the background of trisomy 21
Treating thalassemia twice, in mice
Haematopoietic stem cells can sense tissue damage in the gut
Promising news for gene therapy for sickle cell disease
Related Articles
August 28, 2020
SCD LentiGlobin gene therapy: new data on VOC and ACS
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com